Clinical Trial

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Study acronym: CLEOPATTRA
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-04-28
notable Trial sites expanded: 285 -> 289 locations 2026-04-28
Trial Details
NCT Number NCT07207811
Lead Sponsor Novo Nordisk A/S
Conditions Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Enrollment 1,280 participants
Start Date 2025-10-02
Primary Completion 2029-06-29 (estimated)
Study Completion 2029-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-06-25